menu
    • menu

    Company profile for Bristol Myers Squibb

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. ...
    Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Each day, our employees around the world work together for patients – it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bristol Myers SquibbUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    430 E. 29th Street, 14th Floor, New York, NY 10016
    Telephone
    Telephone
    +1 (212) 546 4000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bms.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/bristol-myers-squibb
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/BMSNEWS

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    🎙️Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 214

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3947

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Bristol Myers to invest $40 billion in the US over 5 years
    Bristol Myers to invest $40 billion in the US over 5 years

    06 May 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-invest-40-billion-us-over-5-years-ceo-says-2025-05-05/

    REUTERS
    06 May 2025
    Share Share
    BMS prunes NJ workforce again, this time to tune of 500+ jobs
    BMS prunes NJ workforce again, this time to tune of 500+ jobs

    06 May 2025

    // FIERCE PHARM

    https://www.fiercepharma.com/pharma/bristol-myers-charts-500-more-layoffs-nj-following-expanded-cost-savings-drive

    FIERCE PHARM
    06 May 2025
    Share Share
    Bristol Myers Squibb Names Cari Gallman EVP, General Counsel & CPO
    Bristol Myers Squibb Names Cari Gallman EVP, General Counsel & CPO

    06 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250506937441/en/Bristol-Myers-Squibb-Appoints-Cari-Gallman-as-Executive-Vice-President-General-Counsel-and-Chief-Policy-Officer

    BUSINESSWIRE
    06 May 2025
    Share Share
    BMS to Close Libertyville Viral Vector Production Facility
    BMS to Close Libertyville Viral Vector Production Facility

    02 May 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/bms-to-close-libertyville-viral-vector-production-facility/

    CONTRACTPHARMA
    02 May 2025
    Share Share
    BMS Reports Mixed Earnings as Portfolio due to Generic Pressure
    BMS Reports Mixed Earnings as Portfolio due to Generic Pressure

    26 Apr 2025

    // BIOSPACE

    https://www.biospace.com/business/bms-reports-mixed-earnings-as-growth-portfolio-makes-up-for-generic-pressure

    BIOSPACE
    26 Apr 2025
    Share Share
    Bristol Myers Squibb's Q1 2025 Financial Results Reported
    Bristol Myers Squibb's Q1 2025 Financial Results Reported

    24 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250424015046/en/Bristol-Myers-Squibb-Reports-First-Quarter-Financial-Results-for-2025

    BUSINESSWIRE
    24 Apr 2025
    Share Share

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Bristol Myers Squibb and get a quotation

    Bristol Myers Squibb is a supplier offers 91 products (APIs, Excipients or Intermediates).

    Find a price of Tremelimumab bulk with DMF offered by Bristol Myers Squibb

    Find a price of 6-Aminopenicillanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Amino Cephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of 7-Aminodesacetoxycephalosporanic Acid bulk offered by Bristol Myers Squibb

    Find a price of Amikacin bulk offered by Bristol Myers Squibb

    Find a price of Amikacin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Amoxicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Amphotericin B bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Ampicillin Trihydrate bulk offered by Bristol Myers Squibb

    Find a price of Aripiprazole bulk offered by Bristol Myers Squibb

    Find a price of Benzylpenicillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Calcium Amphomycin bulk offered by Bristol Myers Squibb

    Find a price of Carmustine bulk offered by Bristol Myers Squibb

    Find a price of Cefaclor bulk offered by Bristol Myers Squibb

    Find a price of Cefadroxil bulk offered by Bristol Myers Squibb

    Find a price of Cefazolin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephalexin bulk offered by Bristol Myers Squibb

    Find a price of Cephapirin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Cephradine bulk offered by Bristol Myers Squibb

    Find a price of Cloxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Desonide bulk offered by Bristol Myers Squibb

    Find a price of Diethylstilbestrol bulk offered by Bristol Myers Squibb

    Find a price of Dimetridazol bulk offered by Bristol Myers Squibb

    Find a price of Enoxacin bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine bulk offered by Bristol Myers Squibb

    Find a price of Fluphenazine Decanoate bulk offered by Bristol Myers Squibb

    Find a price of Glucosamine Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Halcinonide bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin bulk offered by Bristol Myers Squibb

    Find a price of Hetacillin Potassium bulk offered by Bristol Myers Squibb

    Find a price of Hydroxyurea bulk offered by Bristol Myers Squibb

    Find a price of Insulin bulk offered by Bristol Myers Squibb

    Find a price of Irbesartan bulk offered by Bristol Myers Squibb

    Find a price of Isoniazid bulk offered by Bristol Myers Squibb

    Find a price of Kanamycin Sulfate bulk offered by Bristol Myers Squibb

    Find a price of Methicillin bulk offered by Bristol Myers Squibb

    Find a price of Nystatin bulk offered by Bristol Myers Squibb

    Find a price of Oxacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin G Potassium bulk offered by Bristol Myers Squibb

    Find a price of Penicillin V Potassium bulk offered by Bristol Myers Squibb

    Find a price of Pentamidine Isethionate bulk offered by Bristol Myers Squibb

    Find a price of Piperacillin Sodium bulk offered by Bristol Myers Squibb

    Find a price of Piperazine bulk offered by Bristol Myers Squibb

    Find a price of Sodium Dicloxacillin bulk offered by Bristol Myers Squibb

    Find a price of Tetracycline Hydrochloride bulk offered by Bristol Myers Squibb

    Find a price of Tipredane bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Acetonide bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Diacetate bulk offered by Bristol Myers Squibb

    Find a price of Triamcinolone Hexacetonide bulk offered by Bristol Myers Squibb

    Find a price of Triflupromazine bulk offered by Bristol Myers Squibb

    Find a price of Vitamin B12 bulk offered by Bristol Myers Squibb

    Find a price of Warfarin Sodium bulk offered by Bristol Myers Squibb

    Find a price of MDX-015 (ANTI-IL15 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of MFG. ANALYTICAL SPECS. & METHODS OF ANALYSIS FOR MEL B (ARSOBAL) bulk offered by Bristol Myers Squibb

    Find a price of PERSONNEL FOR PUERTO RICO PLANTS bulk offered by Bristol Myers Squibb

    Find a price of FORMULAS: RHODIAL & BOUQUET 5886 bulk offered by Bristol Myers Squibb

    Find a price of PATIENT STARTER PACKAGES bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES AND CONTROLS PERSONNEL FOR MANUFACTURE AND CONTROL bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-067) TO HEPARANASE bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN BARCELONETA, PUERTO RICO - PREVIOUSLY AN ANTIBIOTIC FILE bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-060) TO CD30 bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES. bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (PM-81) TO HUMAN MYELOID DIFFERENTIATION ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of TESTOLACTONE TABLETS, 250 MG bulk offered by Bristol Myers Squibb

    Find a price of PICCOLITE RESIN S 115 L bulk offered by Bristol Myers Squibb

    Find a price of BIS (2-HYDROXY-5-CHLORO PHENYL) SULFIDE bulk offered by Bristol Myers Squibb

    Find a price of COMPOUND SQ 21, 286 bulk offered by Bristol Myers Squibb

    Find a price of MANUFACTURE OF HYDROXYUREA bulk offered by Bristol Myers Squibb

    Find a price of TESTING FACILITIES FOR RAW MATERIALS & FINISHED GOODS bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES FOR THE MFG. OF SEMISOLIDS IN HUMACAO, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-214) TO THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) bulk offered by Bristol Myers Squibb

    Find a price of FACILITIES LOCATED IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of MURINE MONOCLONAL ANTIBODY (ALPHA CTLA4) TOCTLA4 bulk offered by Bristol Myers Squibb

    Find a price of MDX-1303 VALORTIM (TM), ANTI-BACILLUS ANTHRACIS PROTECTIVE ANTIGEN HUMAN MONOCLONAL ANTIBODY bulk offered by Bristol Myers Squibb

    Find a price of PROLIXIN ELIXIR (FLUPHENAZINE HYDROCHLORIDE) bulk offered by Bristol Myers Squibb

    Find a price of JM-9 FOR INJECTION bulk offered by Bristol Myers Squibb

    Find a price of POT. MELARSONYL-mel W (TRIMELARSAN)-MFG, SPECS, & METH. OF ANALYSIS bulk offered by Bristol Myers Squibb

    Find a price of HYDROCHLORIDE 6484 R.P. (VET MED) bulk offered by Bristol Myers Squibb

    Find a price of PLASTIC CONTAINERS bulk offered by Bristol Myers Squibb

    Find a price of LISTING OF INDS bulk offered by Bristol Myers Squibb

    Find a price of DROCINONIDE PHOSPHATE POTASSIUM bulk offered by Bristol Myers Squibb

    Find a price of SUMMARIES OF THE BACKGROUND & QUALIFICATION OF INVEST & MONITORS bulk offered by Bristol Myers Squibb

    Find a price of TRI-BUFFERED BUFFERIN bulk offered by Bristol Myers Squibb

    Find a price of HUMAN MONOCLONAL ANTIBODY (MDX-070) TO PROSTATE SPECIFIC MEMBRANE ANTIGEN bulk offered by Bristol Myers Squibb

    Find a price of METHODS, FACILITIES, AND CONTROLS IN MAYAGUEZ, PUERTO RICO bulk offered by Bristol Myers Squibb

    Find a price of RICIN CONJUGATED MURINE MONOCLONAL ANTIBODY (MDX-RA) TO HUMAN LENS EPITHELIAL CELLS bulk offered by Bristol Myers Squibb

    Find a price of MDX-1100 (ANTI-CXCL 10/ANTI-IP-10 HUMAN MONOCLONAL ANTIBODY) bulk offered by Bristol Myers Squibb

    Find a price of Abatacept bulk offered by Bristol Myers Squibb

    Find a price of Elotuzumab bulk offered by Bristol Myers Squibb

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search